by Gina Shaw
Rare diseases and oncology topped the list of new drug approvals in 2015, according to Diplomat’s report on new drug approvals and the pipeline for 2016, published on Jan. 6. Of the 54 new drugs and biologics approved last year—a figure that tied the FDA’s record for most drugs approved in a single year—25 were rare disease drugs and 13 were oncology agents. More than half of the 54 were considered specialty drugs.
The pipeline seems primed for